Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab in Newly Diagnosed Extranodal Marginal Zone Lymphoma
NCT06569680Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in extranodal marginal zone lymphoma (ENMZL). Started Nov 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
extranodal marginal zone lymphoma (ENMZL)
Beyond the preview
Go deeper on NCT06569680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569680.